Fintel reports that on April 10, 2025, Stifel initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK ...

Fintel reports that on April 10, 2025, Stifel initiated coverage of Ligand Pharmaceuticals Incorporated - Equity Right (OTCPK ...

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Cysteinyl leukotrienes (CysLTs) are potent bronchoconstrictors, playing pivotal roles in inflammatory diseases. These lipid ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings ...

Chemists and chemical engineers at California Institute of Technology, working with a pair of colleagues from the University ...

Stifel initiated coverage of Ligand (LGND) with a Buy rating and $143 price target Ligand, which provides “an important source of ...

Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...

A decade-long study finds that obesity is associated with a significantly increased risk for biologic treatment failure in ...

For the first time, scientists have characterized a promethium coordination complex, advancing the understanding of ...

The study explores whether Prolia/Xgeva (denosumab), a widely used therapy for osteoporosis and bone tumors, can regenerate ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) was the target of a large increase in short interest in ...